|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07K 16/28 | (2006.01) |
| C07K 16/2878 | (2013.01) | ||
| A61K 39/00 | (2006.01) | ||
| A61K2039/505 | (2013.01) | ||
| C07K2317/76 | (2013.01) | ||
| C07K 16/2818 | (2013.01) | ||
| A61P 35/00 | (2018.01) |
| (11) | Number of the document | 3464368 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17730629.7 |
| Date of filing the European patent application | 2017-06-01 | |
| (97) | Date of publication of the European application | 2019-04-10 |
| (45) | Date of publication and mention of the grant of the patent | 2023-06-28 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2017/035521 |
| Date | 2017-06-01 |
| (87) | Number | WO 2017/210473 |
| Date | 2017-12-07 |
| (30) | Number | Date | Country code |
| 201662344866 P | 2016-06-02 | US | |
| 201662382839 P | 2016-09-02 | US |
| (72) |
FARSACI, Benedetto , US
JOSEPHSON, Neil , US
CAO, Anthony , US
HEISER, Ryan , US
|
| (73) |
Bristol-Myers Squibb Company ,
Route 206 and Province Line Road, Princeton, NJ 08543,
US
Seagen Inc. , 21823 30th Drive S.E., Bothell, WA 98021, US |
| (54) | USE OF AN ANTI-PD-1 ANTIBODY IN COMBINATION WITH AN ANTI-CD30 ANTIBODY IN LYMPHOMA TREATMENT |
| USE OF AN ANTI-PD-1 ANTIBODY IN COMBINATION WITH AN ANTI-CD30 ANTIBODY IN LYMPHOMA TREATMENT |